Dr Patrik Andersson

The Unit's Affiliated Memberships aim to facilitate or enhance long-term collaborations between scientists and experts from across the world with the MRC Toxicology Unit and its groups. Affiliated Members are linked to a group and provide the Affiliates with access to the Unit, its expertise and wider opportunities, making them highly valued members of the Unit's research community.

Biography

Patrik received a PhD in Toxicology from Karolinska Institutet, Stockholm, in 2003. After a short postdoc period at Gothenburg University, he joined AstraZeneca in Gothenburg, Sweden 2004 as “Discovery Toxicologist”, leading the safety work from target identification to candidate selection for numerous projects. From 2012, he developed into an expert in the safety of nucleotide-based drugs and their delivery. This includes leading the non-clinical safety work internally at AstraZeneca and in collaborations with world leading companies in the fields of antisense oligonucleotides and therapeutic mRNA.

Research Interests

Patrik currently supervises mechanistic research of oligonucleotide toxicity with a specific focus on hybridization dependent off-target effects. He is an author of several peer reviewed primary and review papers and book chapters in the area of preclinical safety assessment of oligonucleotide therapeutics and active member in several cross-industry collaboration groups aiming to provide industry perspectives to Health Authorities and development of regulatory guidelines. Most recently he was an active member of the EFPIA/PDEG and IQ/DruSafe oligo working groups and leading the Oligo Safety Working Group (OSWG) subcommittee that resulted in a recently accepted paper on revised industry recommendations for off-target safety assessment.